CAR T-Cell Therapy in Multiple Myeloma Webcast 2

CE / CME

CAR T-Cell Therapy in Multiple Myeloma: Understanding and Communicating Safety Evidence

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Nurse Practitioners: 0.75 Nursing contact hours, includes 0.75 hour of pharmacotherapy credit

Released: January 30, 2025

Expiration: July 29, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case: AEs After CAR T-cell Infusion



  • JD received cilta-cel infusion for R/R MM

  • 48 hr after infusion, he developed fever, dizziness, and shortness of breath

  • He required vasopressor support as well as high-flow nasal cannula

  • Additional workup, including lab tests and imaging, were not suggestive of acute infection  

In addition to supportive care with a vasopressor and high-flow nasal cannula, what is the most appropriate intervention to manage JD’s grade 3 CRS?